To further investigate whether the TGF-β2/Smad pathway is required for the biological functions of KDM4C in lung cancer, cells blocked pharmacologically using SD70 were simultaneously treated with LY2109761, a novel TGF-β receptor type I/II dual inhibitor which inhibits the activation of the TGF-β2/Smad signaling pathway (Fig. 6b). Here, TGFB2 is linked to lung carcinoma.